NRG Oncology RTOG 1014: 1 Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (3D-CRT PBrI) for In-Breast Recurrence

摘要

PurposeNRG Oncology RTOG 1014 is a prospective phase II trial of 3D-CRT PBrI following repeat lumpectomy for in-breast recurrence following previous whole breast irradiation (WBI). The primary goal of the trial was to determine the associated toxicity, tolerance and safety of PBrI.